Table 1 Identification of high risk human papilloma viruses in prostate cancer

McNichol 1991 [11] Canada

PCR

14/27 52%

1/5 20%

0.391 ns

Anwar 1992 [12] Japan

PCR

28/68 41%

0/10 0%

0.002 s

Ibrahim 1992 [13] US

PCR

6/48 13%

2/16 13%

1.00 ns

Rotola 1992 [14] Italy

PCR

6/8 75%

14/17 82%

0.885 ns

Dodd 1993 [15] Canada

PCR

3/7 43%

5/10 50%

0.861 ns

Moyret-Lalle 1995 [16] France

PCR hybridisation

9/17 53%

7/22 32%

0.393 ns

Wideroff 1996 [17] US

PCR

7/56 13%

4/42 10%

0.679 ns

Terris 1997 [18] US

PCR

10/53 19%

5/37 14%

0.569 ns

Serth 1999 [19] Germany

PCR

10/47 21%

1/37 3%

0.026 s

Carozzi 2004 [20] Italy

PCR

14/26 54%

5/25 20%

0.117 ns

Leiros 2005 [21] Argentina

PCR

17/41 42%

0/30 0%

0.002 s

Silvestre 2009 [22] Brazil

HPV genotyping

2/65 3%

0/6 0%

Martinez-Fierro 2010 [23] Mexico

PCR

11/55 20%

4/75 5%

0.022 s

Aghakhani 2011 [24] Iran

PCR

13/104 13%

8/104 8%

0.298 ns

Chen 2011 [25] Australia

PCR

7/51 14%

3/11 27%

0.715 ns

Tachezy 2012 [26] Czech

PCR

2/95 2%

1/51 2%

Whitaker 2013 [37] Australia

In situ, standard PCR

29/50 58%

8/50 16%

0.003 s

Ghasemian 2013 [27] Iran

PCR

5/29 17%

8/167 5%

0.025 s

Mokhtari 2013 [28] Iran

IHC

3/30 10%

1/90 1%

Michopoulou 2014 [29] Greece

PCR

8/50 16%

1/30 3%

0.115 ns

Singh 2015 [30]India

PCR

39/95 41%

11/55 20%

0.056 s

Huang 2016 [31]China

PCR

30/75 40%

9/73 12%

0.003 s

Davila Rodriquez 2016 [32] Mexico

HPV genotyping

12/62 19%

1/25 4%

0.107 ns

Atashafrooz 2016 [33] Iran

PCR

32/200 16%

2/100 2%

0.001 s

Medel Flores 2018 [34] Mexico

PCR

37/189 20%

16/167 10%

0.022 s

Nahand 2020 [35] Iran

PCR

19/58 33%

5/32 16%

0.171 ns

Fatemipour 2021 [36] Iran

PCR

26/72 36%

7/44 16%

0.074 ns